New Study: Mail-Service Pharmacies Likely To Improve Prescription Drug AdherenceConsumers receiving their
prescription medications for chronic conditions through a mail-service
pharmacy "were more likely to take them as prescribed by their doctors than did patients who obtained them from a local
pharmacy," according to a new study published in the American Journal of Managed Care...
Source: mnt.toNew Study Confirms Inappropriate Use Of Sedative Hypnotics By Elderly May Increase Adverse Events, Health Care CostsA new study provides important evidence that the use of certain potentially inappropriate medications (PIMs) among the elderly may increase adverse events and health care costs. Among the key study findings was that patients receiving sedative hypnotics (classified as Beers high-severity, or BHS) were significantly more likely (22 percent) to suffer a fall or fracture than control subjects...
Source: mnt.toCT Brain Perfusion Scans Safety Investigation: Initial Notification [UPDATED 12/07/2009]
FDA identified at least 50 additional patients exposed to excess radiation; interim recommendations for imaging facilities provided.
Source: www.fda.govNorpramin (desipramine hydrochloride) - Dear Healthcare Professional Letter Risk of sudden death and cardiac dysrhythmias in patients being treated with Norpramin.
Source: www.fda.govScientists Find New Use For Near-Infrared Spectroscopy: Pill QualityScientists at the University of Maryland, Baltimore have successfully used near-infrared spectroscopy (NIR) -- a method already used to test farm product quality -- to predict how quickly pills dissolve in the body. The experiments could lead to cost savings for drug makers and more consistency in the quality of pills, says Stephen Hoag, PhD, professor, University of Maryland School of
Pharmacy...
Source: mnt.toGENFIT: Potential For Combination Of GFT505 With StatinsGENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, announces the absence of a safety risk due to pharmacokinetic drug-drug interaction when GFT505 is co-administered with a statin (GFT505-1095 clinical study)...
Source: mnt.to
# posted by Network @ 10:07 PM
